Circulating microRNAs May Be Predictive of Degenerative Cervical Myelopathy

Area of Science:

• Basic Science
• Biomarkers
• Neuroscience

Background:

• Degenerative cervical myelopathy (DCM) diagnosis relies on clinical assessment and imaging.
• Currently, no specific serum markers exist for DCM diagnosis.
• Identifying novel biomarkers is crucial for improved DCM management.

Purpose of the Study:

• To identify a unique serum profile of circulating miRNAs and inflammatory markers in DCM patients.
• To compare these profiles against healthy controls (HC).
• To explore potential diagnostic and therapeutic targets for DCM.

Main Methods:

• Collected venous blood from DCM patients and age/gender-matched HC.
• Extracted and screened miRNAs to identify dysregulation in DCM.
• Utilized RT-qPCR for specific miRNA analysis (miR-223-3p, miR-451a).
• Performed bioinformatics analysis for gene networks and miRNA targets.
• Assessed serum inflammatory profiles using a pro-inflammatory panel.

Main Results:

• Two miRNAs, miR-223-3p (upregulated) and miR-451a (downregulated), were differentially expressed in DCM.
• Bioinformatics identified a neurological disease-associated gene network with miR-233-3p targeting over 100 genes.
• Significant upregulation of pro-inflammatory cytokines was observed in DCM patients compared to HC.
• Thirty-six DCM patients and 35 HC were enrolled.

Conclusions:

• DCM patients exhibit a distinct circulating miRNA signature and inflammatory profile.
• These findings suggest potential utility of identified miRNAs as diagnostic or prognostic markers.
• The identified biomarkers may represent future therapeutic targets for degenerative cervical myelopathy.